AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s ...

SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity New study results ...

New study results presented at the European Lung Cancer Congress, ELCC, 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s (AZN) ...

Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option ...

(AZN.L, AZN) announced that new study results presented at the European Lung Cancer Congress (ELCC) 2025, demonstrated the role of the company's TAGRISSO (osimertinib), as monotherapy and as the ...